Valeant reports falling revenue for third consecutive quarter: 3 report insights

Laval, Canada-based Valeant Pharmaceuticals reported a 12.9 percent fall in its fourth quarter revenue, Reuters reports.

Here are three report insights.

1. Valeant's revenues fell 12.9 percent from $2.79 billion to $2.40 billion. The quarter is Valeant's third consecutive quarter of double-digit losses.

2. Valeant's net losses increased to $515 million in Q4.

3. Valeant has been attempting to "rebuild its business and regain investor confidence," after an investigation into its accounting and pricing methods, Reuters reports.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast